Johnson & Johnson (JNJ)
Cancer victims lose bid to block proposed J&J talc bankruptcy
A federal judge on Friday rejected a bid by a group of cancer victims to block Johnson & Johnson from pursuing a proposed bankruptcy settlement of tens of thousands of lawsuits alleging the company's baby powder and other talc products contain cancer-causing asbestos.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Is Johnson & Johnson Stock a Buy?
Johnson & Johnson is trying a new approach to resolve thousands of outstanding talc lawsuits. The company's operations are growing in the mid-single digits, and investors can expect more of the same in the years ahead.
Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors
Johnson & Johnson (JNJ) closed the most recent trading day at $147.19, moving -1.29% from the previous trading session.
Is Johnson & Johnson the Best Dividend Stock for You?
You can confidently buy and hold Johnson & Johnson indefinitely. Its steady, high-single-digit returns can stack up over time.
Two High Conviction Dividend Buys For This Upside-Down Market
FOMO is driving stock market decisions, especially with meme stocks like GameStop and high-flying AI stocks. That's why I prefer discounted dividend stocks over growth stocks, and highlight two picks that offer durable capital returns. Both names carry strong balance sheets, pay well-above market average dividend yields, and are trading at substantial discounts to their historical valuations.
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
J&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's disease. This marks the second sBLA filing for Tremfya in three months.
Johnson & Johnson (JNJ) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Johnson & Johnson (JNJ) closed at $145.65, marking a -0.21% move from the previous day.
J&J hit with new class action over talc seeking medical monitoring for cancer
Johnson & Johnson is facing a new proposed class action seeking damages and medical monitoring on behalf of women who have been diagnosed with cancer, or might develop it in the future, allegedly as a result of using the company's baby powder and other talc products.
3 Mega Cap Stock Bargains As Markets Hit All-Time Highs
As markets continue to reach new all-time highs, investors are constantly seeking opportunities that offer both stability and growth potential. With the S&P 500 and Nasdaq recently hitting new all-time highs, investors are out bargain hunting.
Johnson & Johnson (JNJ) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
